What is the FUJIFILM Wako HCC Risk Biomarkers (AFP-L3 & DCP)?
FUJIFILM Wako's HCC risk biomarkers AFP-L3 and DCP are intended for in vitro diagnostic use as an aid in the risk assessment of patients with chronic liver disease for the development of hepatocellular carcinoma (HCC), supporting early liver cancer detection programmes. Supplied by KRIMS Meditech Solutions with installation, commissioning, application training and maintenance support across Africa.
What is it used for?
Hepatology clinics, liver cancer screening programmes, clinical laboratories.
Key features
- AFP-L3 and DCP assays
- HCC risk assessment
- supports early detection programmes.
Technical considerations
Verified against the official FUJIFILM Healthcare product page. Detailed configuration options and technical specifications available from KRIMS on request.
Specifications should be confirmed against official Fujifilm documentation before purchase decisions. Where a specification is not listed here, KRIMS will confirm it with the manufacturer on request.
Who may need it?
- Facility types: Hospitals, Teaching Hospitals, Government, Military, NGOs, Private Healthcare
How to evaluate this equipment
When reviewing Biotechnology Research Equipment, healthcare facilities should assess clinical fit with existing workflows, compliance with applicable standards, integration with installed systems, serviceability, and the availability of qualified biomedical engineering support in their region.
Purchasing considerations
- Availability: On Request
KRIMS provides end-to-end support including supply, installation, commissioning, calibration, preventive maintenance and operator training. Request a quote for current pricing and delivery schedules for the FUJIFILM Wako HCC Risk Biomarkers (AFP-L3 & DCP) (AFP-L3 / DCP).
